TEM slips nearly 7% as stock remains below major moving averages despite new contracts

TEM slips nearly 7% as stock remains below major moving averages despite new contracts
Tempus ai drops 6.73% today

Tempus AI (TEM) dropped 6.73% after quarterly results, with selling pressure deepening despite robust growth in revenue and strategic new contracts. The down move is reinforced by the stock’s position below all major moving averages and technical signals showing persistent downside momentum.

TEM price prediction
24H -0.43%
$53.81
48H -0.39%
$53.83
7D -3.79%
$51.99
1M 16.08%
$62.73
3M -18.39%
$44.1
6M -38.45%
$33.26
12M 0.07%
$54.08
Current price: $54.04 -5.5500 9.31%
Closed 11/20
Daily range 53.27 Arrow from to Icon 58.24
Weekly range 53.27 Arrow from to Icon 69.40
Loading...

Highlights

  • Tempus AI reported $411.5 million in third-quarter 2026 revenue, up 23% year over year with increased oncology and data segment performance.
  • The company renewed a multi-year $200 million master agreement with AstraZeneca and entered a $55 million collaboration with Pathos, supporting future revenue.
  • Shares of Tempus AI trade below key moving averages with persistent downside momentum and an expected five-day range of $50.19 to $60.6.

Future revenue support as new contracts and insider sales alter sentiment

Tempus AI reported third-quarter 2026 revenue of $411.5 million, reflecting a 23% year-over-year increase, alongside strong growth in oncology units and its Data & Applications segment. The company renewed its master services agreement with AstraZeneca, securing a $200 million multi-year commitment, and entered a $55 million collaboration with Pathos, both expected to support future revenue. Key executives sold shares to cover tax obligations associated with vesting restricted stock units. An agreement to acquire Personalis, a cancer-testing company, is pending shareholder approval and expected to close in the fourth quarter of 2026, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees Tempus AI in a technically vulnerable position. He points to the stock’s drop below all major moving averages and strong downside momentum, despite healthy revenue and new contracts. Kharitonov notes that key executive share sales and the pending Personalis acquisition are unlikely to offset entrenched selling. He is concerned about the dominance of sellers and the risk of taking out recent support levels. "Until momentum indicators turn and the $57.57 ceiling is reclaimed, I remain skeptical about any sustainable upside for Tempus AI."
Viktoras Karapetjanc, expert at Traders Union, views Tempus AI’s fundamental backdrop as a source of potential opportunity. He highlights the 23% revenue growth, key multi-year partnerships, and acquisitions that bolster the long-term outlook. Karapetjanc emphasizes that strong commercial wins with AstraZeneca and Pathos lay the groundwork for further gains once near-term pressure subsides. He remains constructive on the company’s data-driven oncology expansion and sees the current retracement as a market reaction rather than trend disruption. "The bullish structure remains intact — I expect the market to reward these strategic moves once technical stabilization occurs."
Parshwa Turakhiya, analyst, observes heavy sentiment-driven selling with volatility elevated near $55 support. He notes technical exhaustion signals emerging, but warns that buyers remain sidelined for now. Turakhiya sees short-term price action pinned to the lower end of the forecast band, leaving room for quick reversals if momentum turns. "There’s a setup for tactical traders — if $55.05 fails, expect pressure toward $50.19, but a snapback above $57.57 could fuel sharp relief rallies."
Tempus AI asset chart
Tempus AI price dynamics. Source: TradingView.

Persisting bearish momentum as price stalls below technical barriers

Tempus AI is trading below its 20-day, 50-day, and 200-day moving averages, with the current price at $55.6 compared to $72.78 (MA-20), $72.89 (MA-50), and $57.57 (MA-200). This alignment signals persistent selling pressure across short, medium, and long-term trends. The 200-day moving average at $57.57 acts as a near-term ceiling, while today’s low at $55.05 serves as immediate support. Momentum readings remain bearish, with the MACD and ADX indicating downside momentum and a lack of trend strength. The RSI is neutral and does not show signs of exhaustion, but both the Stochastic RSI and CCI are in oversold zones, suggesting some short-term selling exhaustion risks. Bear Power remains negative, intraday sellers dominate, and the Awesome Oscillator confirms prevailing negative momentum. The stock is down $4.01 or 6.73% on the session, following a sizeable downside gap of about $1.62 (2.72%), with the price pinned near the low. Intraday volatility measures 5.99%.

Earlier, analysts noted that Tempus AI's robust revenue growth and expanded commercial partnerships established a broadly bullish technical outlook despite short-term price weakness. The current breakdown below major moving averages and persistent downside momentum signals a shift to a more cautious stance, making the $55.05 support a pivotal level to watch for signs of stabilization or further declines.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.